X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with Unichem Lab - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs UNICHEM LAB - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA UNICHEM LAB AJANTA PHARMA/
UNICHEM LAB
 
P/E (TTM) x 24.2 29.0 83.4% View Chart
P/BV x 10.0 3.1 326.5% View Chart
Dividend Yield % 0.6 0.6 96.8%  

Financials

 AJANTA PHARMA   UNICHEM LAB
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-16
UNICHEM LAB
Mar-16
AJANTA PHARMA/
UNICHEM LAB
5-Yr Chart
Click to enlarge
High Rs1,720334 515.0%   
Low Rs1,103174 633.9%   
Sales per share (Unadj.) Rs194.6146.9 132.5%  
Earnings per share (Unadj.) Rs45.211.9 380.2%  
Cash flow per share (Unadj.) Rs50.316.2 310.7%  
Dividends per share (Unadj.) Rs8.002.00 400.0%  
Dividend yield (eoy) %0.60.8 72.0%  
Book value per share (Unadj.) Rs132.0105.1 125.6%  
Shares outstanding (eoy) m88.7790.84 97.7%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x7.31.7 419.5%   
Avg P/E ratio x31.221.4 146.2%  
P/CF ratio (eoy) x28.115.7 178.8%  
Price / Book Value ratio x10.72.4 442.4%  
Dividend payout %17.716.8 105.2%   
Avg Mkt Cap Rs m125,29923,073 543.0%   
No. of employees `000NA5.7 0.0%   
Total wages/salary Rs m2,5702,558 100.5%   
Avg. sales/employee Rs ThNM2,352.5-  
Avg. wages/employee Rs ThNM450.9-  
Avg. net profit/employee Rs ThNM190.4-  
INCOME DATA
Net Sales Rs m17,27513,346 129.4%  
Other income Rs m166192 86.7%   
Total revenues Rs m17,44213,538 128.8%   
Gross profit Rs m5,8071,639 354.3%  
Depreciation Rs m451390 115.5%   
Interest Rs m4929 169.8%   
Profit before tax Rs m5,4741,412 387.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-4 0.0%   
Extraordinary Inc (Exp) Rs m0-35 0.0%   
Tax Rs m1,460293 498.8%   
Profit after tax Rs m4,0141,080 371.5%  
Gross profit margin %33.612.3 273.7%  
Effective tax rate %26.720.7 128.7%   
Net profit margin %23.28.1 287.0%  
BALANCE SHEET DATA
Current assets Rs m7,6395,979 127.8%   
Current liabilities Rs m2,7152,432 111.6%   
Net working cap to sales %28.526.6 107.2%  
Current ratio x2.82.5 114.4%  
Inventory Days Days4363 68.5%  
Debtors Days Days7960 130.3%  
Net fixed assets Rs m6,9146,403 108.0%   
Share capital Rs m177182 97.4%   
"Free" reserves Rs m11,4429,293 123.1%   
Net worth Rs m11,7219,548 122.7%   
Long term debt Rs m149230 64.5%   
Total assets Rs m14,81412,843 115.3%  
Interest coverage x112.950.0 225.7%   
Debt to equity ratio x00 52.6%  
Sales to assets ratio x1.21.0 112.2%   
Return on assets %27.48.6 317.6%  
Return on equity %34.211.3 302.7%  
Return on capital %46.514.3 324.6%  
Exports to sales %55.129.2 188.7%   
Imports to sales %6.06.3 94.7%   
Exports (fob) Rs m9,5273,900 244.3%   
Imports (cif) Rs m1,038847 122.5%   
Fx inflow Rs m10,4224,356 239.2%   
Fx outflow Rs m1,6781,162 144.4%   
Net fx Rs m8,7443,194 273.7%   
CASH FLOW
From Operations Rs m3,2641,119 291.6%  
From Investments Rs m-2,093-853 245.3%  
From Financial Activity Rs m-1,186-334 354.8%  
Net Cashflow Rs m-15-68 21.7%  

Share Holding

Indian Promoters % 73.8 50.1 147.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 1.6 15.1 10.3%  
FIIs % 7.6 3.0 253.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 31.7 53.6%  
Shareholders   20,968 20,176 103.9%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   ELDER PHARMA  FDC LTD.  SHASUN PHARMA  FRESENIUS KABI ONCO.  TTK HEALTHCARE  

Compare AJANTA PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes Marginally Lower; Capital Goods & Realty Stocks Fall(Closing)

Indian share markets witnessed selling pressure in the final hour of trade to finish just below the dotted line. At the closing bell, the BSE Sensex closed lower by 71 points.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Feb 20, 2018 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA - FRESENIUS KABI ONCO. COMPARISON

COMPARE AJANTA PHARMA WITH

MARKET STATS